Erin Cobain

Erin Cobain
Clinical Associate Professor of Internal Medicine, Medical School
Office:
University of Michigan Medical School
Internal Medicine Hematology/Oncology
1500 E Medical Center Drive
Ann Arbor, Michigan 48109
Email:
[email protected]
Available to mentor
Erin Cobain
Erin Cobain
Clinical Associate Professor
  • About
  • Links
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
  • Manage Your Profile

  • About

    Erin F. Cobain, MD is a Clinical Associate Professor in the Division of Hematology/Oncology, where she specializes in the treatment of patients with breast cancer. She received her undergraduate degree from Davidson College, which she received a B.S. in Biology and graduated cum laude and Phi Beta Kappa. She received her medical degree from the University of Chicago Pritzker School of Medicine. She completed her Internal Medicine residency at the Hospital of the University of Pennsylvania, where she also served as Chief Medical Resident. Dr. Cobain completed her fellowship in Hematology/Oncology at the University of Michigan, where she was also Chief Fellow. She joined the faculty at the University of Michigan in 2016. Dr. Cobain’s research interest is primarily in the application of next-generation sequencing technology in oncology clinical practice.  She also has an interest in the use of tumor biomarkers to direct and personalize patient care. She works in collaboration with the Michigan Oncology Sequencing Center (Mi-OncoSeq program) to study the clinical outcomes of patients with advanced malignancies undergoing comprehensive next-generation sequencing analysis of their tumors.

    Links

    • Profile - University of Michigan
    • Rogel Cancer Center

    Qualifications

    • Fellow
      University of Michigan Medical School, Internal Medicine, Ann Arbor, United States
      2013 - 2016
      Other
    • Chief Resident
      Hospital of the University of Pennsylvania, Internal Medicine, Philadelphia, United States
      2012 - 2013
      Chief Resident
    • Resident
      Hospital of the University of Pennsylvania, Internal Medicine, Philadelphia, United States
      2010 - 2012
      Residency
    • Intern
      Hospital of the University of Pennsylvania, Internal Medicine, Philadelphia, United States
      2009 - 2010
      Internship
    • MD
      University of Chicago Pritzker School of Medicine, 924 E. 57th Street, Room 104, Chicago, IL, 60637, United States
      2005 - 2009

    Center Memberships

    • Center Member
      Rogel Cancer Center

    Research Overview

    Next generation sequencing of tumor and blood to identify therapeutic targets for patients with advanced cancer
    Next-generation sequencing of matched tumor and normal samples to identify inherited cancer susceptibility
    Identification of tumor biomarkers in breast cancer that predict benefit from immunotherapy

    Recent Publications

    See All Publications
    • Proceeding / Abstract / Poster
      Multicenter retrospective study of clinical genetic testing in patients with sarcoma.
      Wilbur HC, Cobain E, Wiesner GL, Davis EJ, Chugh R. 2022 Jun 13;
    • Proceeding / Abstract / Poster
      Multicenter retrospective study of clinical genetic testing in patients with sarcoma.
      Wilbur HC, Cobain E, Wiesner GL, Davis EJ, Chugh R. 2022 Jun 13;
    • Chapter
      Bladder Cancer
      Cobain EF, Mooney CJ, Smith DC. TUMOR BOARD REVIEW: GUIDELINE AND CASE REVIEWS IN ONCOLOGY, SECOND EDITION, 2015 TUMOR BOARD REVIEW: GUIDELINE AND CASE REVIEWS IN ONCOLOGY, SECOND EDITION, 207 - 216.
      PMID: BC1DS
    • Presentation
      Optimal Treatment Strategies for CDK4/6 Inhibitor Resistant Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
      2026 Feb 3;
    • Presentation
      Emerging Therapies in ER-+/ HER2-neg Metastatic Breast Cancer: SERDs, ESR1 Targeting, CDK4/6 Sequencing, and ADCs
      Cobain E. 2026 Aug 28;
    • Presentation
      Use of Gene Expression Profiling to Refine Neoadjuvant Systemic Therapy Approaches in Early-Stage Hormone Receptor Positive, HER2 Negative Breast Cancer.
      Cobain E. 2026 Aug 28;
    • Presentation
      Carrying Risk, Creating a Plan: Cancer Risk Management in Unaffected Carriers with Hereditary Breast and Ovarian Cancer (HBOC) Syndromes
      Cobain E. 2026 Aug 28;
    • Presentation
      Who Benefits? Defining a Role for Neoadjuvant Chemo-Immunotherapy in HR-Positive/HER2-Negative Breast Cancer
      Cobain E. 2026 Aug 28;